LT-1951
Phase 1- Indications
- Saphenous vein graft disease, Coronary artery bypass graft failure
Company intelligence / Profile preview
Lumen Therapeutics
Menlo Park, California, United Statesbiospace.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
In 2005, Lumen Therapeutics began a Phase I/IIA clinical trial for LT-1951, a treatment to prevent graft failure following saphenous vein coronary artery bypass graft surgery. The drug naturally penetrates into veins, suppresses neointimal hyperplasia, and allows grafts to develop strengthened walls, making them less prone to failure over time[4].
- Therapeutic areas
- Cardiovascular
- Modalities
- Peptides (oligo-L-arginine based drugs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Lumen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lumen Therapeutics.